MarÃ-a L De Ceballos

List of Publications by Year
in descending order

80	5,066	126708	88477
papers	citations	33 h-index	70 g-index

83	83	83	6902
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation. Journal of Neuroscience, 2005, 25, 1904-1913.	1.7	670
2	The Transcription Factor Nrf2 Is a Therapeutic Target against Brain Inflammation. Journal of Immunology, 2008, 181, 680-689.	0.4	424
3	Cannabidiol and Other Cannabinoids Reduce Microglial Activation In Vitro and In Vivo: Relevance to Alzheimer's Disease. Molecular Pharmacology, 2011, 79, 964-973.	1.0	305
4	Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. Glia, 2010, 58, 588-598.	2.5	301
5	Transcription factor NFE2L2/NRF2 is a regulator of macroautophagy genes. Autophagy, 2016, 12, 1902-1916.	4.3	300
6	Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Research, 2001, 61, 5784-9.	0.4	298
7	Prolonged oral cannabinoid administration prevents neuroinflammation, lowers Î²-amyloid levels and improves cognitive performance in Tg APP 2576 mice. Journal of Neuroinflammation, 2012, 9, 8.	3.1	196
8	Leptin regulates glutamate and glucose transporters in hypothalamic astrocytes. Journal of Clinical Investigation, 2012, 122, 3900-3913.	3.9	168
9	Increased cannabinoid CB1receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. European Journal of Neuroscience, 2001, 14, 1827-1832.	1.2	166
10	Molecular reorganization of endocannabinoid signalling in Alzheimerâ€™s disease. Brain, 2011, 134, 1041-1060.	3.7	164
11	Cannabinoids Protect Astrocytes from Ceramide-induced Apoptosis through the Phosphatidylinositol 3-Kinase/Protein Kinase B Pathway. Journal of Biological Chemistry, 2002, 277, 36527-36533.	1.6	145
12	The AMP-Activated Protein Kinase Is Involved in the Regulation of Ketone Body Production by Astrocytes. Journal of Neurochemistry, 2002, 73, 1674-1682.	2.1	110
13	Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmoset. Brain Research, 1991, 567, 127-132.	1.1	94
14	Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by <scp>l</scp>â€ÐOPA. European Journal of Neuroscience, 2008, 27, 580-592.	1.2	89
15	Sex differences in the phagocytic and migratory activity of microglia and their impairment by palmitic acid. Glia, 2018, 66, 522-537.	2.5	83
16	Synthesis of glycosyl derivatives as dopamine prodrugs: interaction with glucose carrier GLUT-1Electronic supplementary information (ESI) available: experimental details for the preparation of all derivatives and biological assays. See http://www.rsc.org/suppdata/ob/b2/b212066f/. Organic and Biomolecular Chemistry, 2003, 1, 767-771.	1.5	69
17	Î²-Amyloid25-35 inhibits glutamate uptake in cultured neurons and astrocytes: modulation of uptake as a survival mechanism. Neurobiology of Disease, 2004, 15, 580-589.	2.1	67
18	Neurotensin, substance P, delta and mu opioid receptors are decreased in basal ganglia of parkinson's disease patients. Neuroscience, 1994, 61, 73-79.	1.1	66

#	Article	IF	Citations
19	Leptin gene therapy attenuates neuronal damages evoked by amyloid-Î² and rescues memory deficits in APP/PS1 mice. Gene Therapy, 2014, 21, 298-308.	2.3	64
20	Chronic antidepressant treatment increases enkephalin levels in n. Accumbens and striatum of the rat. European Journal of Pharmacology, 1985, 112, 119-122.	1.7	63
21	Ghrelin Regulates Glucose and Glutamate Transporters in Hypothalamic Astrocytes. Scientific Reports, 2016, 6, 23673.	1.6	62
22	Hypoalgesia induced by antidepressants in mice: A case for opioids and serotonin. European Journal of Pharmacology, 1986, 125, 193-199.	1.7	61
23	Effects of a unilateral 6-hydroxydopamine lesion and prolonged L-3,4-dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia. European Journal of Pharmacology, 1992, 219, 183-192.	1.7	56
24	Î²-Amyloid Peptides Are Cytotoxic to Astrocytes in Culture: A Role for Oxidative Stress. Neurobiology of Disease, 2000, 7, 395-405.	2.1	53
25	Prenatal exposure of rats to antidepressant drugs down-regulates beta-adrenoceptors and 5-HT2 receptors in cerebral cortex. Neuropharmacology, 1985, 24, 947-952.	2.0	52
26	Alterations in peptide levels in Parkinson's disease and incidental Lewy body disease. Brain, 1996, 119, 823-830.	3.7	51
27	Do enkephalins in basal ganglia mediate a physiological motor rest mechanism?. Movement Disorders, 1986, 1, 223-233.	2.2	48
28	Stimulation of brain glucose uptake by cannabinoid CB2 receptors and its therapeutic potential in Alzheimer's disease. Neuropharmacology, 2016, 110, 519-529.	2.0	43
29	Striatal neuropeptide levels in Parkinson's disease patients. Neuroscience Letters, 1992, 145, 171-174.	1.0	42
30	Alzheimer's disease: relationship between muscarinic cholinergic receptors, Î²â€amyloid and tau proteins. Fundamental and Clinical Pharmacology, 1998, 12, 473-481.	1.0	42
31	Down-regulation of 3H-imipramine binding sites in rat cerebral cortex after prenatal exposure to antidepressants. Life Sciences, 1990, 46, 1597-1600.	2.0	41
32	Synthesis and Atypical Antipsychotic Profile of Some 2-(2-Piperidinoethyl)benzocycloalkanones as Analogs of Butyrophenone. Journal of Medicinal Chemistry, 1994, 37, 2564-2573.	2.9	36
33	Normal aging in rats and pathological aging in human Alzheimerâ€™s disease decrease FAAH activity: Modulation by cannabinoid agonists. Experimental Gerontology, 2014, 60, 92-99.	1.2	36
34	Changes in molecular isoform distribution of acetylcholinesterase in rat cortex and cerebrospinal fluid after intracerebroventricular administration of amyloid Î²-peptide. Neuroscience Letters, 2002, 325, 199-202.	1.0	31
35	Cortical expression of brain derived neurotrophic factor and type-1 cannabinoid receptor after striatal excitotoxic lesions. Neuroscience, 2008, 152, 734-740.	1.1	30
36	Synthesis and antidopaminergic activity of some 3-(aminomethyl)tetralones as analogs of butyrophenone. Journal of Medicinal Chemistry, 1991, 34, 2242-2247.	2.9	29

#	Article	IF	Citations
37	Characterization of neurotensin-like immunoreactivity in human basal ganglia: Increased neurotensin levels in substantia nigra in Parkinson's disease. Peptides, 1995, 16, 339-346.	1.2	29
38	Repeated intracerebroventricular administration of Î²-amyloid 25â€“35 to rats decreases muscarinic receptors in cerebral cortex. Neuroscience Letters, 2000, 278, 69-72.	1.0	28
39	Acute effects of D-1 and D-2 dopamine receptor agonist and antagonist drugs on basal ganglia [Met5]- and [Leu5]-enkephalin and neurotensin content in the rat. Biochemical Pharmacology, 1991, 41, 1385-1391.	2.0	25
40	Long-lasting changes after perinatal exposure to antidepressants. Progress in Brain Research, 1988, 73, 173-187.	0.9	24
41	Alterations in [Met5]- and [Leu5]enkephalin and neurotensin content in basal ganglia induced by the long-term administration of dopamine agonist and antagonist drugs to rats. European Journal of Pharmacology, 1986, 130, 305-309.	1.7	23
42	The GSK-3-inhibitor VP2.51 produces antidepressant effects associated with adult hippocampal neurogenesis. Neuropharmacology, 2017, 116, 174-187.	2.0	23
43	Neuropeptide levels in the basal ganglia of aged common marmosets following prolonged treatment with MPTP. Journal of Neural Transmission Parkinson's Disease and Dementia Section, 1991, 3, 99-108.	1.2	22
44	Prenatal exposure of rats to antidepressants enhances agonist affinity of brain dopamine receptors and dopamine-mediated behaviour. European Journal of Pharmacology, 1985, 116, 257-262.	1.7	20
45			

#	Article	IF	Citations
55	5-HT2 antagonist activity of 3-aminomethyltetralones. Bioorganic and Medicinal Chemistry Letters, 1991, 1, 717-720.	1.0	13
56	Antinociceptive effects in rodents of the dipeptide Lys-Trp (Nps) and related compounds. Peptides, 1986, 7, 39-43.	1.2	12
57	Acute and repeated administration of sulpiride alters Met- and Leu-enkephalin content of rat brain. Neuroscience Letters, 1986, 68, 322-326.	1.0	12
58	Isocratic reverse-phase HPLC separation and RIA used in the analysis of neuropeptides in brain tissue. Neuropeptides, 1991, 20, 201-209.	0.9	12
59	Circannual variation in opioid receptor sensitivity in mouse vas deferens. European Journal of Pharmacology, 1984, 106, 227-228.	1.7	11
60	Pyridazine derivatives XII. Synthesis and antipsychotic-antidepressant activity of some butyrophenone derivatives of 6-phenylpyridazine. European Journal of Medicinal Chemistry, 1994, 29, 831-839.	2.6	11
61	Effects of Video Game Training on Behavioral and Electrophysiological Measures of Attention and Memory: Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2017, 6, e8.	0.5	11
62	GABA modulation of cholinergic transmission in rat oviduct. Life Sciences, 1984, 35, 357-364.	2.0	9
63	Butyrophenone analogues: Synthesis of 2-methyl-3-ethyl-5-aminoethyl-4,5,6,7-tetrahydroindol-4-ones, and their affinities for d1, d2 and 5-ht2a receptors. Bioorganic and Medicinal Chemistry Letters, 1995, 5, 579-584.	1.0	9
64	Targeting Cannabinoid Receptor Activation and BACE-1 Activity Counteracts TgAPP Mice Memory Impairment and Alzheimerâ€™s Disease Lymphoblast Alterations. Molecular Neurobiology, 2020, 57, 1938-1951.	1.9	8
65	Amyloid-Î²1-40 differentially stimulates proliferation, activation of oxidative stress and inflammatory responses in male and female hippocampal astrocyte cultures. Mechanisms of Ageing and Development, 2021, 195, 111462.	2.2	8
66	Boosting brain glucose metabolism to fight neurodegeneration?. Oncotarget, 2017, 8, 14273-14274.	0.8	7
67	Î²-Amyloid-Induced Cytotoxicity, Peroxide Generation and Blockade of Glutamate Uptake in Cultured Astrocytes. Clinical Chemistry and Laboratory Medicine, 2001, 39, 317-8.	1.4	6
68	Impaired hippocampal glucoregulation in the cannabinoid CB1 receptor knockout mice as revealed by an optimized in vitro experimental approach. Journal of Neuroscience Methods, 2012, 204, 366-373.	1.3	6
69	Preliminary research on 1-(4-bromo-2-nitroimidazol-1-yl)-3-[18 F]fluoropropan-2-ol as a novel brain hypoxia PET tracer in a rodent model of stroke. European Journal of Medicinal Chemistry, 2015, 101, 604-615.	2.6	6
70	Cannabinoids for the treatment of neuroinflammation. , 2015, , 3-14.		4
71	Synthesis and Inhibitory Activities against Aminopeptidase B and Enkephalin-Degrading Enzymes of Ketomethylene Dipeptide Analogues of Arphamenines. Archiv Der Pharmazie, 1992, 325, 3-8.	2.1	3
72	The role of cannabinoids in preventing the neurodegenerative process occurring in Alzheimer's disease. Drugs of the Future, 2005, 30, 807.	0.0	3

#	Article	IF	Citations
73	Analgesic dipeptide derivatives. Part 8. 3-Amino-2-hydroxy-4-[2-(o-nitrophenylthio)indol-3-yl]butanoic acid [AH(Nps)IBA]-containing dipeptide analogues of the analgesic compound H-Trp(Nps)-Lys-OMe. Journal of the Chemical Society Perkin Transactions 1, 1991, , 2749-2755.	0.9	2
74	Prolonged antinociceptive activity of pseudodipeptide analogues of Lys-Trp(Nps) and Trp(Nps)-Lys. Peptides, 1992, 13, 63-67.	1.2	2
75	Analgesic dipeptide derivatives. 7. 3,7-Diamino-2-hydroxyheptanoic acid (DAHHA) containing dipeptide analogs of the analgesic compound H-Lys-Trp(Nps)-OMe. Journal of Medicinal Chemistry, 1992, 35, 889-895.	2.9	2
76			